Summary Flagellate erythema is characterized by “whiplike’’ linear streaks, usually following bleomycin chemotherapy or is associated with consumption of shiitake mushrooms, dermatomyositis, adult onset still disease as well as human immunodeficiency disease. Here, we describe a case of bleomycin-induced flagellate erythema in a patient with Hodgkin lymphoma.
Hodgkin Disease--drug therapy

Lymphoma is one of the most common malignancies in China. In China, there were 6 829 new Hodgkin lymphoma cases and 2 807 deaths in 2020, with 92 834 new non-Hodgkin lymphoma cases and 54 351 deaths. Due to the complicated pathological subtypes and heterogeity, the treatment strategies for lymphoma vary largely. In recent years, with the deep understanding for the nature of lymphoma, much research progress has been achieved in the diagnosis and treatment, leading to a remarkable improvement in survival outcome of patients. In order to update the progress in the treatment of lymphoma worldwide timely, and further improve the level of standardized diagnosis and treatment of lymphoma in China, the China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical practice guideline for lympoma in China (2021 Edition)" .
China/epidemiology* ; Hodgkin Disease/drug therapy* ; Humans ; Lymphoma/therapy* ; Lymphoma, Non-Hodgkin/drug therapy* ; Medical Oncology

No abstract available.
Cyclophosphamide* ; Drug Therapy, Combination* ; Hodgkin Disease* ; Procarbazine* ; Vincristine*

Primary pulmonary involvement of Hodgkin's disease is unusual, and can be distinguished from nodal Hodgkin's disease involving the lung secondarily. We report a case of with primary pulmonary manifestation of Hodgkin's disease in young woman who survived 2 years after diagnosis with literature reviews. She had unilateral cavitating lung lesions. After pathological examination, we diagnosed as primary pulmonary Hodgkin's disease, mixed cellularity type and treated with conventional chemotherapy and adjuvant radiation.
Diagnosis ; Drug Therapy ; Female ; Hodgkin Disease* ; Humans ; Lung ; Lung Neoplasms

PURPOSE: Despite intensive search for the optimal combination chemotherapy for aggres- sive non-Hodgkins lymphoma (NHL), the CHOP regimen is still the standard therapy. We investigated the clinical efficacy of ProMACE-CytaBOM, a third generation regimen, in patients with advanced aggressive NHL. MATERIALS AND METHODS: We prospectively analyzed the therapeutic approach and the outcome in 33 patients with previously untreated aggressive NHL enrolled into the protocol from June 1994 to June 1997. RESULTS: Objective response was achieved in 93.9% of the patients. Complete response (CR) and partial response were 54.5% and 39.4%, respectively. The mean time to CR was 75.4 days. CR rate was significantly lower in patients aged 50 years or more (31.3% vs 76.5%, p=0.009). Five year overall (OS) and failure-free survival (FFS) rate were 56.1% and 47.2%, respectively. The age, attainment of CR, and mean relative dose intensity influenced OS significantly (p=0.002, p=0.005 and p=0.039, respectively). The age and attainment of CR influenced FFS significantly (p=0.001 and p=0.003, respec- tively). In patients aged 50 or more, mean relative dose intensity of less than 72% was more frequent than younger age group (73.3% vs 33.3%, p=0.003). There was one toxic death (3.0%). CONCLUSION: The survival rate of present study was similar to that of previously report concerning ProMACE-CytaBOM. The outcome of elderly NHL patients was poor, and dose intensity may be correlated with the outcome.
Aged ; Drug Therapy, Combination ; Hodgkin Disease* ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin ; Prospective Studies ; Survival Rate

Rituximab is a human/murine chimeric anti-CD20 mono- clonal antibody used to treat CD20-positive B-cell non- Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymp-tomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non- Hodgkin's lymphoma.
B-Lymphocytes ; Chills ; Drug Therapy ; Fever ; Flushing ; Hodgkin Disease ; Humans ; Lymphoma, Non-Hodgkin ; Pneumonia* ; Skin ; Rituximab

PURPOSE: To assess the efficacy and toxicity of a new protocol that consists of CHOP- Bleo alternated with a new regimen of Cyclophosphamide, methotrexate, etoposide, and dexamethasone(CMED) for aggressive Non-Hodgkin's Lymphoma(NHL). PATIENTS AND METHODS: Between January 1991 and December 1996, forty-six patients with Ann Arbor stages II-IV aggressive NHL were treated with alternating cycles of CHOP-Bleo and CMED for a total of 12 cycles. All eligible patients were evaluated for response, disease-free survival, and overall survival. RESULTS: Twenty-two patients(47.8%) achieved a complete response and overall response rate was 83.9%. The range of survival duration was 1-68+months and the median survival time was 42 months. Overall 3-year survival rate was 54%. The range of disease-free survival time was 6-63+months and 3-year disease-free survival rate was 61%. The most common hematologic toxicity was leukopenia and the incidence of severe leukopenia(<1,000/mm3) was 11%. And alopecia(84.8%) was the most common non-hematologic toxicity. CONCLUSION: The results of CHOP-Bleo/CMED alternating chemotherapy for patients with aggressive Non-Hodgkin's Lymphoma is not superior to other results of previous studies. Therefore further study will be warranted to determine clinical effectiveness of alternating chemotherapy.
Cyclophosphamide ; Disease-Free Survival ; Drug Therapy* ; Etoposide ; Hodgkin Disease* ; Humans ; Incidence ; Leukopenia ; Lymphoma, Non-Hodgkin ; Methotrexate ; Survival Rate

The malignant lymphoma originating in the parotid gland is relatively rare, constituting 0.3% of all reported malignancies. Malignant lymphoma is a neoplastic proliferation of cell in the lymphoreticular system and devided as Hodgkin's disease and non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma occurs primarily in lymph nodes and is rarely found in extralymphatic organs. In general, malignant lymphoma originating in the parotid gland is histologically described as non- Hodgkin's lymphoma, frequently belongs to the B-cell type and rarely relapses into other sites. Recently, we have experienced a malignant lymphoma in the left parotid gland. It was diffuse large B-cell type, stage I. In the imaging examination, exhibited homogeneity of the tumor. It was well defined margin and no infiltration into the adjacent tissue. The patient underwent superficial parotidectomy and combination chemotherapy with CHOP-regimen. He have been followed for 6 months and no relapse occurred. We report this case with a brief review of literature.
B-Lymphocytes ; Drug Therapy, Combination ; Hodgkin Disease ; Humans ; Lymph Nodes ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Parotid Gland* ; Recurrence

PURPOSE: Ga-67 scintigraphy has been used for the evaluation of tumors, especially lymphoma. Recently, Tl-201 and Tc-99m MIBI were also used to tumor imaging. Tl-201 and Tc-99m MIBI had better physiologic characteristics than Ga-67, so we studied 32 biopsy proven lymphoma patients (male 24, female 8, mean age 46 years) with Ga-67, Tl-201 or Tc-99m MIBI and compared the scan findings. MATERIALS AND METHODS: Twenty-three of 32 patients were injected 74-111 MBq (2-3 mCi) of Tl-201, before chemotherapy and imaged with dual-headed SPECT (Prism 2000, Picker, USA) at 30 minutes after injection. Delayed images were obtained after 3 hr in 8 patients. Twenty seven of 32 patients were injected 740 MBq (20 mCi) of Tc-99m MIBI and imaged at 30 minutes after injection. 111-185 MBq (3-5 mCi) of Ga-67 was injected in 12 patients and imaged at 48 and 72 hours after injection. Twenty eight patients were diagnosed as non-Hodgkin's lymphoma and others were Hodgkin's lymphoma. RESULTS: Twenty patients were positive on Tl-201 scan and 3 patients showed negative findings. One of these 3 patients, Tc-99m MIBI and Ga-67 scan were positive. Twenty two patients were positive on Tc-99m MIBI scan and 5 patients showed negative findings. One of these 5 patients, Tl-201 was positive and 2 were positive on Ga-67 scan. Ten of 12 patients showed positive findings on Ga-67 scan. The sensitivity of these agents were 83.3%, 87.0% and 81.5% for Ga-67, Tl-201 and Tc-99m MIBI, respectively. The sensitivity was highest in Tl-201 scan, but there were no significant differences among three tests. In this study, there was no significant difference of uptake ratios between early and delayed images of Tl-201. CONCLUSION: Scintigraphy with Tl-201 and Tc-99m MIBI in lymphoma patients have similar sensitivity with Ga-67.
Biopsy ; Drug Therapy ; Female ; Hodgkin Disease ; Humans ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Radionuclide Imaging ; Tomography, Emission-Computed, Single-Photon

PURPOSE: To assess the ability of FDG PET for the detection of bone marrow infiltration compared to iliac crest biopsy in patients with lymphoma. MATERIALS AND METHODS: Seventy-three patients (30 females and 43 males, mean age of 47 years old) with malignant lymphoma (4 Hodgkin's disease, HD and 69 Non-Hodgkin's lymphoma, NHL) were included. FDG PET was performed for staging in 53 patients and to assess treatment response after the completion of chemotherapy in 20 patients. Final conclusions were based on biopsy, other imaging studies, or clinical follow-up. RESULTS: There were 54 (74%) of the 73 patients in whom FDG PET and iliac crest biopsy were concordant. Forty-seven of the 54 patients showed concordant negative results while the remaining 7 patients had concordant positive results. Of 19 patients with discordant results, FDG PET accurately detected bone marrow infiltration in 6 patients with negative iliac crest biopsy. On the contrary, iliac crest biopsy identified bone marrow infiltration in 12 of the 19 patients. In remaining one of the 19 patients with discordant results, iliac crest biopsy was true negative but FDG PET was falsely positive. CONCLUSION: FDG PET seems to be an adjunct in detecting marrow infiltration that may not be revealed by iliac crest biopsy at staging. For the assessment of treatment response, it may be less helpful than biopsy in detecting microscopic residual disease in the bone marrow.
Biopsy ; Bone Marrow* ; Drug Therapy* ; Female ; Follow-Up Studies ; Hodgkin Disease ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin ; Male